Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib
NCT06983691
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2+ Metastatic Breast Cancer (MBC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Duke University
- Last updated on ClinicalTrials.gov
- September 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.